LIFETECH SCI (01302) announced that on May 22, 2026, the company intends to acquire approximately 96.46% of the equity in Beijing Huayi Shengjie Technology Co., Ltd. from the seller, AUT-VII HK Holdings Limited. The transaction consideration is approximately RMB 1.873 billion. This consideration will be paid by the company issuing convertible bonds to the seller. Upon completion of the transaction, Huayi Shengjie will become a non-wholly owned subsidiary of the company, and its financial performance will be consolidated into the group's financial statements.

As a medical device company, Huayi Shengjie is primarily engaged in the research and development, manufacturing, and sales of vascular interventional medical devices. The company's products are mainly used for treating congenital heart defects and preventing cardiogenic embolic strokes. Huayi Shengjie launched one of China's first domestically produced congenital heart defect occluders in 2003 and introduced China's first patent foramen ovale (PFO) occluder product in 2009.

Huayi Shengjie focuses on the R&D, manufacturing, and sales of vascular interventional medical devices, possessing competitive advantages in proprietary technology, market access, and R&D capabilities. The board of directors believes that the acquisition of Huayi Shengjie aligns with the group's overall development strategy and will bring long-term benefits to the company.